V2 sact_regimen
781,388 rows · 12 columns
| ENCORE_PATIENT_ID | MERGED_REGIMEN_ID | HEIGHT_AT_START_OF_REGIMEN | WEIGHT_AT_START_OF_REGIMEN | INTENT_OF_TREATMENT | DATE_DECISION_TO_TREAT | START_DATE_OF_REGIMEN | MAPPED_REGIMEN | CLINICAL_TRIAL | CHEMO_RADIATION | BENCHMARK_GROUP | LINK_NUMBER |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 20125096 | 20134185 | 0 | 64.7 | Palliative (P) | 2010-05-02 | 2014-12-06 | Doxorubicin + Olaratumab | N | N | IPILIMUMAB + NIVOLUMAB | 101249771 |
| 20125195 | 20134187 | 1.65 | null | Adjuvant (A) | 2020-10-22 | 2021-03-05 | EOF | 02 | N | TOPOTECAN | 100966435 |
| 20125231 | 20134188 | 1.5 | 63.7 | Palliative (P) | 2018-09-05 | 2019-02-23 | Nilotinib | null | N | AFLIBERCEPT + FLUOROURACIL + IRINOTECAN | 100036978 |
| 20125466 | 20134190 | 1.58 | 95 | null | 2018-01-13 | 2018-01-13 | Lomustine | 02 | null | BINIMETINIB + CETUXIMAB + ENCORAFENIB | 101059715 |
| 20125547 | 20134192 | 1.77 | 90 | Disease modification (D) | 2016-07-14 | 2016-07-14 | CISPLATIN + TEYSUNO | 01 | null | COSMIC TRIAL | 100696043 |
| 20125581 | 20134193 | 1.75 | 94.6 | Palliative (P) | 2017-11-11 | 2017-11-18 | CAPE + OXALIPLATIN + TRASTUZUMAB | 02 | N | PHITT D SIOPEL-4 (A1, A2, A3) | 101179710 |
| 20125601 | 20134194 | 1.72 | 91.2 | Palliative (P) | 2020-10-27 | 2021-01-06 | COSMIC TRIAL | N | N | IFOSFAMIDE | 101471204 |
| 20125802 | 20134196 | 0 | 0 | null | 2018-07-30 | 2018-10-07 | Doxorubicin + Olaratumab | 99 | null | CYCLOPHOSPHAMIDE + EPIRUBICIN + FLUOROURACIL | 100714583 |
| 20125855 | 20134198 | 1.66 | 81 | null | 2018-10-12 | 2018-10-12 | OXALIPLATIN + MDG + PANITUMUMAB | 02 | null | CARBOPLATIN + CYCLOPHOSPHAMIDE + DOXORUBICIN + PACLITAXEL | 100650315 |
| 20125986 | 20134199 | 1.56 | 80 | Palliative (P) | 2018-07-30 | 2018-12-03 | LOMUSTINE + MDG | 02 | N | CISPLATIN + FLUOROURACIL + TRASTUZUMAB | 100261119 |
| 20126014 | 20134200 | 1.79 | 62.8 | Palliative (P) | 2017-04-27 | 2017-05-03 | Cisplatin + Fluorouracil + RT 5day | 02 | N | CISPLATIN + RT | 101616001 |
| 20126124 | 20134201 | 1.69 | 49.9 | Adjuvant (A) | 2016-12-17 | 2017-04-29 | IRINOTECAN + MDG + PANITUMUMAB | N | N | CARBOPLATIN + FLUOROURACIL + STREPTOZOCIN | 100320021 |
| 20126178 | 20134203 | 1.58 | 64 | null | 2019-06-29 | 2019-06-30 | Cisplatin + Vinorelbine (PO) | 99 | N | BENDAMUSTINE + OBINUTUZUMAB | 101160470 |
| 20126182 | 20134204 | 1.69 | 73.9 | Palliative (P) | null | 2020-08-15 | CARBOPLATIN + FLUOROURACIL | N | N | HEPATOBLASTOMA SR CISPLATIN | 101707757 |
| 20126335 | 20134206 | 1.54 | 74.4 | Disease modification (D) | 2019-03-09 | 2019-07-27 | IDELALISIB | 02 | null | ANAGRELIDE | 101034990 |
| 20126429 | 20134207 | 1.56 | 76 | Palliative (P) | 2020-09-21 | 2020-10-05 | ECarboX | 02 | N | CARBOPLATIN + PEMETREXED | 100168636 |
| 20127030 | 20134209 | 1.72 | 65 | Palliative (P) | 2018-09-11 | 2018-09-23 | ECF | 02 | N | BALLAD TRIAL | 100414289 |
| 20127112 | 20134210 | 1.56 | 70 | Curative (C) | 2022-05-01 | 2022-05-20 | Gemcitabine 300mg/m2 + RT | 02 | null | CISPLATIN + TRASTUZUMAB | 101414123 |
| 20127274 | 20134211 | 1.81 | 95.9 | Palliative (P) | 2017-04-22 | 2017-04-22 | DARATUMUMAB | 02 | N | CISPLATIN + DOCETAXEL + FLUOROURACIL | 101510282 |
| 20127322 | 20134212 | 1.8 | 78.5 | null | 2020-08-13 | 2021-06-02 | SCOPE 2 TRIAL | 2 | null | CYCLOPHOSPHAMIDE + DOXORUBICIN + RITUXIMAB + VINCRISTINE | 100078050 |
| 20127354 | 20134213 | 1.8 | 71 | null | 2019-11-11 | 2019-11-11 | COSMIC TRIAL | 02 | N | CYCLOPHOSPHAMIDE + DOXORUBICIN + RITUXIMAB + VINCRISTINE | 100668601 |
| 20127387 | 20134214 | 0 | 59.8 | null | 2020-06-04 | 2020-06-10 | Bevacizumab + Irinotecan + MdG | 02 | null | TOPOTECAN | 100568877 |
| 20128098 | 20134218 | 1.65 | 74.6 | Adjuvant (A) | 2016-02-13 | 2016-03-09 | FCiSt | 02 | N | HYDROXYCARBAMIDE | 100152128 |
| 20128237 | 20134219 | 1.46 | 83.9 | 03 | 2016-10-27 | 2016-10-27 | EC | N | N | CARBOPLATIN + CETUXIMAB + FU | 100001782 |
| 20128390 | 20134221 | null | null | null | 2018-02-01 | 2018-08-14 | CISPLATIN + RALTITREXED | null | N | CISPLATIN + RT | 101565674 |
| 20128415 | 20134222 | 1.77 | 87.9 | Neo-adjuvant (N) | 2021-02-24 | 2021-03-07 | Topotecan (oral) | 02 | N | DARATUMUMAB | 101708384 |
| 20128425 | 20134223 | 1.75 | 115.9 | Palliative (P) | 2020-12-07 | 2020-12-15 | CARBOPLATIN + FLUOROURACIL | 02 | null | CHLORAMBUCIL + PROCARBAZINE + VINBLASTINE | 101186030 |
| 20128510 | 20134224 | 1.56 | 61.1 | Palliative (P) | 2017-11-28 | 2017-11-30 | null | 02 | Y | ABEMACICLIB + FULVESTRANT | 100391618 |
| 20128598 | 20134225 | 1.61 | null | Curative (C) | 2020-05-03 | 2020-05-23 | Trastuzumab + VINORELBINE | 02 | null | FOXTROT TRIAL | 100656961 |
| 20128706 | 20134226 | 1.57 | 81.4 | Palliative (P) | 2017-11-23 | 2017-11-23 | CAPECITABINE + LOMUSTINE | 02 | null | CISPLATIN + FLUOROURACIL + RT | 101099294 |
| 20128711 | 20134227 | 1.79 | 67.3 | Curative (C) | 2018-01-06 | 2018-01-06 | PACLITAXEL + RAMUCIRUMAB | 02 | N | CYCLOPHOSPHAMIDE + DOXORUBICIN + VINCRISTINE | 101513469 |
| 20128758 | 20134228 | 1.66 | 65 | null | 2019-05-07 | 2019-05-14 | Radium 223 | Y | null | CARBOPLATIN + EPIRUBICIN + FLUOROURACIL | 100056430 |
| 20128905 | 20134230 | 1.57 | 56 | Curative (C) | 2018-10-18 | 2018-10-30 | CABOZANTINIB | N | N | GEMCITABINE + RT | 100812538 |
| 20129019 | 20134231 | 1.61 | 81 | null | 2016-07-03 | 2016-07-10 | CAPECITABINE + IRINOTECAN + Panitumumab | N | N | IRINOTECAN + MDG + PANITUMUMAB | 101536188 |
| 20129056 | 20134232 | null | null | Curative (C) | 2020-11-05 | 2020-12-13 | Rituximab + Venetoclax | N | null | CYCLOPHOSPHAMIDE + POMALIDOMIDE | 100477129 |
| 20129164 | 20134234 | 1.71 | 68 | Curative (C) | 2019-12-07 | 2019-12-07 | Capecitabine + Streptozocin | N | N | Y-90 | 101311392 |
| 20129205 | 20134235 | 1.55 | 80.5 | null | 2014-08-23 | 2016-12-24 | STS Rhabdomyosarcoma RMS 2005 IVA | 01 | N | ECARBOX | 100994138 |
| 20129223 | 20134236 | null | null | null | 2017-10-06 | 2017-10-08 | CYCLOPHOSPHAMIDE | 02 | N | ETOPOSIDE + IFOSFAMIDE | 100465742 |
| 20129224 | 20134237 | 1.5 | 54.6 | Palliative (P) | 2017-07-07 | 2018-09-04 | Cisplatin + Fluorouracil + Streptozocin | 02 | N | ERLOTINIB | 100904570 |
| 20129291 | 20134238 | 1.46 | 80 | Not known (9) | 2018-06-13 | 2018-06-17 | Capecitabine+Trastuzumab 21dayMaint | N | N | BEVACIZUMAB + FLUOROURACIL + IRINOTECAN | 101426232 |
| 20129366 | 20134239 | 1.75 | 44.7 | null | 2018-05-25 | 2018-05-30 | Pazopanib | 02 | N | RIBOCICLIB | 100191626 |
| 20129429 | 20134240 | 1.65 | 8.9 | null | 2016-10-12 | 2016-10-17 | Bevacizumab + Oxaliplatin +MdG | 02 | null | IBRUTINIB | 101658040 |
| 20129467 | 20134241 | 1.77 | 68.8 | null | 2019-01-15 | 2019-01-25 | Azacitidine | 02 | N | PACLITAXEL + RAMUCIRUMAB | 100197399 |
| 20129620 | 20134242 | 1.48 | 45.9 | Palliative (P) | 2019-01-29 | 2019-01-29 | Melphalan IV High dose | 02 | N | ERIBULIN | 101556988 |
| 20129652 | 20134243 | 0.92 | 78.9 | 03 | null | 2022-05-05 | PLATO Trials | null | N | THALIDOMIDE | 101248546 |
| 20129699 | 20134244 | 1.75 | 58.5 | Disease modification (D) | null | 2018-12-04 | null | 2 | N | CYCLOPHOSPHAMIDE + FLUDARABINE + RITUXIMAB | 100444251 |
| 20129917 | 20134245 | 1.61 | 119.7 | Palliative (P) | 2018-11-18 | 2018-11-18 | ACELARATE Trial | N | N | CETUXIMAB + MDG | 101225247 |
| 20130142 | 20134246 | 1.79 | 28.6 | null | 2018-11-29 | 2018-11-29 | TEMOZOLOMIDE | 01 | N | RUXOLITINIB | 101542528 |
| 20130428 | 20134247 | 1.77 | 91.2 | null | 2018-11-18 | 2018-11-18 | Docetaxel + Gemcitabine (prior RT) | 02 | null | IBRUTINIB | 100859039 |
| 20130468 | 20134248 | 1.55 | 85.3 | Palliative (P) | 2017-02-02 | 2017-02-09 | Capecitabine + Streptozocin | N | N | GO2 TRIAL | 101289378 |